To this end, murine models suggest that pretherapy elevated tumor glucose uptake as quantified by positron emission tomography (PET) with [18F] fluorodeoxy-glucose (FDG-PET) may predict antitumor activity to mTOR inhibition 9 or those patients more likely to achieve a more durable period of disease control. The gene discussed is MTOR; the disease is neoplasm.